Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECIOUS-01 in Advanced Solid Tumors
NCT04751786Phase 1Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2021
- Primary completion
- Dec 2026
- Modality
- Peptides, Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PRECIOUS-01 in solid tumor, sponsored by Radboud University Medical Center. Primary endpoints: Safety of PRECIOUS-01 (AEs and SAEs) at 17 weeks and Multiplex immunohistochemistry assay for immune cell subsets at 9 weeks. Started Jan 2021; status: active, not recruiting.
02
Drugs
PRECIOUS-01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04751786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04751786.